About BioInvent

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need.  The Company's pipeline currently includes product candidates for the treatment of cancer, thrombosis, atherosclerosis, and inflammatory diseases.

Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR^®, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets.

BioInvent has a high level of competence in antibody drug discovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery, development and manufacturing services to customers.

BioInvent's business model and technology platform have been validated through numerous partnerships. These include a strategic alliance with Roche for the anti-cancer agent TB-403; a co-development agreement with Genentech for BI-204, an antibody which targets atherosclerosis; and a long-term collaboration with ThromboGenics in the fields of cancer and vascular medicine.

BioInvent employs around 100 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.